XENE News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

XE

Mkt Cap

$3.24B

Volume

870.60K

Next Earnings

November 2nd

Loading chart

XE

XENEXenon Pharmaceuticals Inc

XENE

Pay with—

Available Balance0.00

XE

Mkt Cap

$3.24B

Volume

870.60K

Next Earnings

November 2nd

Chart Financials Earnings News About Insider Filings

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?Xenon Pharmaceuticals paused enrollment in phase III depression trials for azetukalner after unexpected neurological and psychiatric side effects emerged, including confusion, speech difficulties, and psychosis cases. The company is reviewing dose adjustments with top-line results expected in Q1 2027. However, Xenon's epilepsy program remains promising, with an FDA application pending for focal onset seizures treatment, offering potential growth opportunities despite the depression program setback.Zacks Investment Research · Oct 15, 2026

XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' SetbackXenon Pharmaceuticals submitted an FDA application for azetukalner to treat focal onset seizures, supported by positive phase IIb and phase III epilepsy studies showing significant seizure reductions. However, the company temporarily paused enrollment in depression studies due to neuropsychiatric adverse events, causing a 27% stock decline in premarket trading. The X-NOVA2 depression study is 80% enrolled with top-line data expected in Q1 2027.Zacks Investment Research · Sep 18, 2026

Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsightThe metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapies and PARP inhibitors reshaping the treatment paradigm. Key emerging drugs include 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and cabozantinib, with multiple pharmaceutical companies advancing innovative treatments in clinical trials.GlobeNewswire Inc. · Jun 10, 2026

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual MeetingXenon Pharmaceuticals announced positive Phase 3 X-TOLE2 study results for azetukalner, a KV7 potassium channel opener for focal onset seizures, showing 53.2% reduction in monthly seizure frequency at 25mg versus 10.4% for placebo. Long-term data from the 48-month X-TOLE open-label extension study demonstrated nearly 40% of participants achieved at least 12 months of seizure freedom. The company plans to submit a New Drug Application to the FDA in Q3 2026.GlobeNewswire Inc. · Apr 19, 2026

Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should KnowXenon Pharmaceuticals' chief medical officer sold 1,410 shares worth $78,000 on March 13, 2026, representing a routine RSU vesting and sell-to-cover transaction. The stock has surged 55% following positive Phase 3 trial results for its lead candidate azetukalner and a $750 million capital raise. Despite significant losses ($345.9M in 2025), the well-capitalized biotech remains a binary bet on its neurological drug pipeline.The Motley Fool · Mar 27, 2026

Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public OfferingXenon Pharmaceuticals priced an upsized public offering of 10.5 million common shares at $57.00 per share and pre-funded warrants, expected to raise approximately $650 million gross proceeds. The offering is expected to close on March 12, 2026, with J.P. Morgan, Jefferies, and other major underwriters managing the deal.GlobeNewswire Inc. · Mar 11, 2026

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 MillionCommodore Capital increased its stake in Spyre Therapeutics by 400,161 shares ($10.46 million) in Q4, bringing its total position to $78.24 million (5.21% of AUM). SYRE stock has surged 63% over the past year, significantly outperforming the S&P 500's 13% gain. The preclinical biotech company, focused on inflammatory bowel disease treatments, has a strong balance sheet with $757 million in cash and expects runway into H2 2028, with six Phase 2 readouts expected in 2026.The Motley Fool · Feb 23, 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Xenon Pharmaceuticals granted 39,250 share options to five new non-officer employees, with options vesting over four years and an exercise price of $44.61 per share.GlobeNewswire Inc. · Dec 4, 2025

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Xenon Pharmaceuticals granted 24,200 share options to six new non-officer employees, with an exercise price of $30.54 per share, vesting over four years.GlobeNewswire Inc. · Aug 1, 2025

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Xenon Pharmaceuticals Inc. announced equity inducement grants to four new non-officer employees, consisting of 78,600 share options and 1,800 performance share units. The share options have an exercise price of $38.28 per common share and vest over four years, while the performance share units will vest based on the achievement of certain predefined milestone-based objectives over an approximately three-year period.GlobeNewswire Inc. · May 2, 2025

to start trading

XE

XENEXenon Pharmaceuticals Inc

XENE

Pay with—

Available Balance0.00

Your PositionYou don't own any XENE yet.

Related Tickers

Earnings